{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:36:06Z","timestamp":1762518966474,"version":"build-2065373602"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24849-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:30:48Z","timestamp":1762518648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-6399","authenticated-orcid":false,"given":"Alexandre","family":"De Moura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orane","family":"Gleizes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Cabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bethune-Volters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Bellesoeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Bello-Roufai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Sebbag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Geiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Escalup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Genev\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"24849_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/bcr777","volume":"6","author":"FJ Esteva","year":"2004","unstructured":"Esteva, F. J. & Hortobagyi, G. N. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6, 109 (2004).","journal-title":"Breast Cancer Res."},{"key":"24849_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl. J. Med. 353, 1673\u20131684 (2005).","journal-title":"N Engl. J. Med."},{"key":"24849_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz, G. et al. APHINITY - Adjuvant Pertuzumab and trastuzumab in early HER2-Positive breast cancer. N Engl. J. Med. 377, 122\u2013131 (2017).","journal-title":"N Engl. J. Med."},{"key":"24849_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney, S. M. et al. Adjuvant Paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl. J. Med. 372, 134\u2013141 (2015).","journal-title":"N Engl. J. Med."},{"key":"24849_CR5","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive Meta-analysis. Clin. Cancer Res. 26, 2838\u20132848 (2020).","journal-title":"Clin. Cancer Res."},{"key":"24849_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. KATHERINE - Trastuzumab emtansine for residual invasive HER2-Positive breast cancer. N. Engl. J. Med. 380, 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"key":"24849_CR7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. EMILIA - Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl. J. Med. 367, 1783\u20131791 (2012).","journal-title":"N Engl. J. Med."},{"key":"24849_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41388-022-02585-3","volume":"42","author":"D Bello Roufai","year":"2023","unstructured":"Bello Roufai, D. et al. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 42, 1951\u20131956 (2023).","journal-title":"Oncogene"},{"key":"24849_CR9","doi-asserted-by":"crossref","unstructured":"De Moura, A. et al. Atezolizumab and Paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program. Sci. Rep. 13\u00a0(2023).","DOI":"10.1038\/s41598-023-40569-9"},{"key":"24849_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","volume":"31","author":"A De Moura","year":"2024","unstructured":"De Moura, A. et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer patients treated at Institut curie hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 31, 572\u2013580 (2024).","journal-title":"Breast Cancer"},{"key":"24849_CR11","first-page":"100772","volume":"37","author":"S Antol\u00edn Novoa","year":"2023","unstructured":"Antol\u00edn Novoa, S. et al. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study). Cancer Treat. Res. Commun. 37, 100772 (2023).","journal-title":"Cancer Treat. Res. Commun."},{"key":"24849_CR12","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini, F. et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat. Rev. 84, 101965 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"24849_CR13","doi-asserted-by":"crossref","unstructured":"Loibl, S. et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. Presented at San Antonio Breast Cancer Symposium 2023, Abstract GS03-12 (2023).","DOI":"10.1158\/1538-7445.SABCS23-GS03-12"},{"key":"24849_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter, F. W. et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br. J. Cancer. 122, 603\u2013612 (2020).","journal-title":"Br. J. Cancer"},{"key":"24849_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol, A. S. et al. Brain metastases. Nat. Rev. Dis. Primers. 5, 5 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"24849_CR16","doi-asserted-by":"publisher","first-page":"591399","DOI":"10.3389\/fonc.2020.591399","volume":"10","author":"N Wilson","year":"2020","unstructured":"Wilson, N., Ironside, A., Diana, A. & Oikonomidou, O. Lobular breast cancer: A review. Front. Oncol. 10, 591399 (2020).","journal-title":"Front. Oncol."},{"key":"24849_CR17","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1200\/JCO.2012.46.2440","volume":"31","author":"O Metzger-Filho","year":"2013","unstructured":"Metzger-Filho, O. et al. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J. Clin. Oncol. 31, 1954\u20131960 (2013).","journal-title":"J. Clin. Oncol."},{"key":"24849_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 689\u2013699 (2014).","journal-title":"Lancet Oncol."},{"key":"24849_CR19","doi-asserted-by":"publisher","first-page":"109805","DOI":"10.1016\/j.radonc.2023.109805","volume":"186","author":"V Salvestrini","year":"2023","unstructured":"Salvestrini, V. et al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 186, 109805 (2023).","journal-title":"Radiother Oncol."},{"key":"24849_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab Deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"24849_CR21","unstructured":"Harbeck, N. et al. Trastuzumab Deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med 1\u201310 (2024)."},{"key":"24849_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano, G. et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2\u2009+\u2009metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol. 33, 321\u2013329 (2022).","journal-title":"Ann. Oncol."},{"key":"24849_CR23","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin, N. U. et al. Intracranial efficacy and survival with Tucatinib plus trastuzumab and capecitabine for previously treated HER2-Positive breast cancer with brain metastases in the HER2CLIMB trial. J. Clin. Oncol. 38, 2610\u20132619 (2020).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24849-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:30:49Z","timestamp":1762518649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24849"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24849-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D Bello-Roufai reported consulting fees from AstraZeneca, MSD and EISAI; support for attending meetings from Daiichi-Sankyo. D Loirat reported consulting fees from AstraZeneca, Daiichi-Sankyo, Roche and Pfizer; support for attending meetings from AstraZeneca, Daiichi-Sankyo and Roche.\u00a0JY Pierga reported consulting fees from AstraZeneca, Daiichi-Sankyo, Novartis, Lilly, Roche, MSD and Gilead; support for attending meetings from AstraZeneca, Novartis, Gilead and Daiichi-Sankyo.\u00a0FC Bidard reported consulting fees from AstraZeneca, Daiichi-Sankyo and Roche; research grants from Pfizer and AstraZeneca; support for attending meetings from AstraZeneca and Daiichi-Sankyo.\u00a0Other authors declared no competing interests with this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39160"}}